Moderna's RSV Vaccine Gains FDA Approval
TL;DR Summary
Moderna has received U.S. FDA approval for its mRNA-based RSV vaccine, mRESVIA, designed to protect adults aged 60 and older from lower respiratory tract disease caused by RSV. This is Moderna's second approved product and the first mRNA vaccine approved for a disease other than COVID-19. The approval follows positive results from a Phase 3 clinical trial, showing high efficacy and no serious safety concerns. Moderna plans to make mRESVIA available in the U.S. by the 2024/2025 respiratory virus season.
- Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R) Moderna Investor Relations
- Moderna Looks For Boost from Newly Approved RSV Shot The Wall Street Journal
- FDA approves Moderna’s mRNA RSV vaccine The Hill
- Moderna wins second product approval with RSV vaccine MarketWatch
- Moderna secures FDA approval for RSV vaccine mRESVIA FiercePharma
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
5 min
vs 6 min read
Condensed
93%
1,090 → 80 words
Want the full story? Read the original article
Read on Moderna Investor Relations